Video

Dr. Rugo on the Utility of Margetuximab in HER2+ Metastatic Breast Cancer

Hope S. Rugo, MD, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

Hope S. Rugo, MD, a professor in the Department of Medicine, Hematology/Oncology, and director, Breast Oncology and Clinical Trials Education, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the utility of margetuximab in HER2-positive metastatic breast cancer.

Margetuximab plus chemotherapy led to a 29% reduction in the risk of disease progression or death versus trastuzumab (Herceptin) plus chemotherapy in the phase III SOPHIA trial. In December 2019, the developers of the HER2-positive antibody submitted a biologics license application for the drug for use in combination with chemotherapy as a treatment for patients with metastatic HER2-positive breast cancer.

Polymorphisms in the IgG Fc gamma receptor have the potential to limit the activity of trastuzumab. However, margetuximab is an Fc engineered HER2-positive antibody designed to enhance IgG1 Fc affinity for the activating Fc gamma receptor and decrease affinity for the inhibitory Fc gamma receptor, explains Rugo.

According to a prespecified exploratory analysis, patients who harbored a CD16A 158F allele had a median overall survival of 23.7 months with margetuximab versus 19.4 months with trastuzumab. These data merit additional investigation of the agent as neoadjuvant therapy in patients with low-affinity IgG Fc gamma receptors, says Rugo.

It remains to be seen how margetuximab might fit into the landscape given the recent approval of fam-trastuzumab deruxtecan-nxhi (Enhertu) and the potential approval of tucatinib in the metastatic setting, concludes Rugo.

Related Videos
Hope S. Rugo, MD
Idoroenyi Amanam, MD
Srikala Sridhar, MD, MSc, FRCPC
Andrea Wolf, MD, MPH
Suzanne Lentzsch, MD, PhD
Domenica Lorusso, MD, PhD
Martin H. Voss, MD
Jacob Sands, MD
Martin H. Voss, MD
Amitkumar Mehta, MD